There is provided FV derivatives that reduce blood clotting activity, by reducing thrombin generation, when compared to wild-type FV. In particular, the FV of the present invention comprises single-point and multi-point mutations, encompassed by aspartic acid 79 to glutamic acid 119. The derivatives can be used to treat patient with conditions necessitating reduced clotting activity.

 
Web www.patentalert.com

< Method of producing and screening antibodies produced in transgenic plants

< Abiotic stress responsive polynucleotides and polypeptides

> 10-Substituted macrolide antibiotics

> Nucleoside compounds for treating viral infections

~ 00298